Biotech Acquisition Co (Biotech Acquisition Co) Other Operating Expense : $3.74 Mil (TTM As of Sep. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Biotech Acquisition Co Other Operating Expense?

Biotech Acquisition Co's Other Operating Expense for the three months ended in Sep. 2022 was $0.25 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Sep. 2022 was $3.74 Mil.

Biotech Acquisition Co's quarterly Other Operating Expense declined from Mar. 2022 ($1.90 Mil) to Jun. 2022 ($1.27 Mil) and declined from Jun. 2022 ($1.27 Mil) to Sep. 2022 ($0.25 Mil).

Biotech Acquisition Co's annual Other Operating Expense stayed the same from . 20 ($0.00 Mil) to Dec. 2020 ($0.00 Mil) but then increased from Dec. 2020 ($0.00 Mil) to Dec. 2021 ($1.57 Mil).

Biotech Acquisition Co Other Operating Expense Historical Data

The historical data trend for Biotech Acquisition Co's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotech Acquisition Co Other Operating Expense Chart

Biotech Acquisition Co Annual Data

Trend

Dec20

Dec21

Other Operating Expense

1.57

Biotech Acquisition Co Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Other Operating Expense	Get a 7-Day Free Trial				0.63	0.33	1.90	1.27	0.25

Biotech Acquisition Co Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.74 Mil.

Biotech Acquisition Co Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Biotech Acquisition Co's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Biotech Acquisition Co (Biotech Acquisition Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Biotech Acquisition Co (NAS:BIOT) » Definitions » Other Operating Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

545 West 25th Street, 20th Floor, New York, NY, USA, 10001

Website

Biotech Acquisition Co is a blank check company.

Executives

Albert F Hummel	director, officer: Chief Investment Officer	PO BOX 3407, RANCHO SANTA FE CA 92067
Biotech Sponsor Llc	10 percent owner	545 W. 25TH ST., 20TH FLOOR, NEW YORK NY 10001
Bruno Montanari	director	545 WEST 25TH STREET, 20TH FLOOR, NEW YORK NY 10001
Ivan Jarry	officer: Chief Operating Officer	545 WEST 25TH STREET, 20TH FLOOR, NEW YORK NY 10001
Paul Bernard	director	545 WEST 25TH STREET 20TH FL, NEW YORK NY 10001
Aaron Kim	director	545 WEST 25TH STREET 20TH FL, NEW YORK NY 10001
Michael Schleifer	director, 10 percent owner, officer: Chief Executive Officer	545 WEST 25TH STREET 20TH FLOOR, NEW YORK NY 10001
Thomas Fratacci	officer: CFO & Treasurer	545 WEST 25TH STREET, 20TH FLOOR, NEW YORK NY 10001

Biotech Acquisition Co (Biotech Acquisition Co) Headlines

From GuruFocus

Biotech Acquisition Company and Blade Therapeutics, Inc. Announce Effectiveness of Registration Statement on Form S-4, Date of BAC's Extraordinary General Meeting to Approve Proposed Business Combination and Signing of Up to $75 million Committed Equity F

By PRNewswire PRNewswire • 05-19-2022

Biotech Acquisition Company and Blade Therapeutics Mutually Agree to Terminate Business Combination Agreement

By PRNewswire PRNewswire • 07-13-2022

Biotech Acquisition Company and Blade Therapeutics Announce Postponement of Extraordinary Meeting of Shareholders to Approve Proposed Business Combination

By PRNewswire PRNewswire • 07-03-2022

Biotech Acquisition Company and Blade Therapeutics Announce Postponement of Extraordinary Meeting of Shareholders to Approve Proposed Business Combination

By PRNewswire PRNewswire • 07-10-2022

Biotech Acquisition Company Announces Submission of Prospectus Supplement to the Proxy Statement/Prospectus to The Registration Statement on Form S-4 Related to Proposed Merger with Blade Therapeutics, Inc.

By PRNewswire PRNewswire • 07-03-2022

By PRNewswire PRNewswire • 06-28-2022

By PRNewswire PRNewswire • 05-24-2022

By PRNewswire PRNewswire • 06-08-2022

Biotech Acquisition Company and Blade Therapeutics Announce Postponement of Extraordinary Meeting of Shareholders to Approve Proposed Business Combination

By PRNewswire PRNewswire • 06-23-2022

By PRNewswire PRNewswire • 07-08-2022